AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia

Cancer

Volumn 120, Issue 16, 2014, Pages 2482-2489

  Cooper, Todd M ^a   Alonzo, Todd A ^b   Gerbing, Robert B ^c   Perentesis, John P ^d   Whitlock, James A ^e   Taub, Jeffrey W ^f   Horton, Terzah M ^g   Gamis, Alan S ^h   Meshinchi, Soheil ⁱ   Loken, Michael R ^j   Razzouk, Bassem I ^k  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h CHILDREN S MERCY HOSPITAL   (United States)

ⁱ USA   (United States)

^j HEMATOLOGICS INC   (United States)

^k Peyton Manning Children's Hospital   (United States)

more..

Author keywords

acute myeloid leukemia; clofarabine; cytarabine; pediatric

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLOFARABINE; CYTARABINE; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANOREXIA; ARTICLE; BONE MARROW APLASIA; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INFECTION; INFESTATION; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SURVIVAL RATE; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DOSE RESPONSE; LEUKEMIA, MYELOID, ACUTE; PRESCHOOL CHILD; YOUNG ADULT;

ADENINE NUCLEOTIDES; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CHILD; CHILD, PRESCHOOL; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; YOUNG ADULT;

EID: 84905663275     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28674     Document Type: Article

References (20)

1. Kersey JH,. Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997; 90: 4243-4251.
2. Pui CH, Carroll WL, Meshinchi S, Arceci RJ,. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29: 551-565.
3. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA 3rd,. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem. 1992; 35: 397-401.
4. Mansson E, Flordal E, Liliemark J, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 2003; 65: 237-247.
5. Parker WB, Shaddix SC, Rose LM, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol. 1999; 55: 515-520.
6. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004; 103: 784-789.
7. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006; 24: 1917-1923.
8. Cooper T, Ayres M, Nowak B, Gandhi V,. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005; 55: 361-368.
9. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005; 105: 940-947.
10. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012; 30: 2492-2499.
11. Cooper TM, Razzouk BI, Gerbing R, et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013; 60: 1141-1147.
12. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011; 118: 6043-6049.
13. Wells RJ, Adams MT, Alonzo TA, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003; 21: 2940-2947.
14. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012; 120: 1581-1588.
15. Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013; 31: 599-607.
16. Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM,. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia. 1999; 13: 25-31.
17. Orgel E, Zung L, Ji L, Finklestein J, Feusner J, Freyer DR,. Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective. Pediatr Blood Cancer. 2013; 60: 1528-1533.
18. Lipshultz SE, Alvarez JA, Scully RE,. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008; 94: 525-533.
19. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK,. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012; 120: 2826-2835.
20. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11: 543-552.